Efficacy of cabazitaxel rechallenge in heavily treated patients with metastatic castration-resistant prostate cancer

CABA rechallenge may be a treatment option without cumulative toxicity in heavily pretreated patients with mCRPC who are still fit and had a progression >3 months after the last CABA injections.